

**Supplementary Table 5. Meta-regression analysis for each US RSS**

Covariates	Intermediate to high risk as positive				High risk as positive			
	Sensitivity (95% CrI)	P-value	Specificity (95% CrI)	P-value	Sensitivity (95% CrI)	P-value	Specificity (95% CrI)	P-value
<b>ACR-TIRADS</b>								
Study design								
Prospective	0.89 (0.79–0.98)	0.792	0.41 (0.16–0.66)	0.476	0.47 (0.22–0.73)	0.440	0.91 (0.83–0.98)	0.054
Retrospective	0.74 (0.62–0.86)		0.34 (0.18–0.49)		0.36 (0.21–0.52)		0.91 (0.86–0.96)	
No. of nodules								
>140	0.75 (0.60–0.89)	0.072	0.48 (0.30–0.66)	0.052	0.37 (0.20–0.54)	0.973	0.93 (0.89–0.97)	0.146
<140	0.84 (0.73–0.95)		0.25 (0.12–0.39)		0.42 (0.20–0.64)		0.87 (0.79–0.95)	
Prevalence of malignance								
>35%	0.86 (0.77–0.95)	>0.99	0.40 (0.19–0.60)	0.427	0.48 (0.29–0.66)	0.177	0.90 (0.84–0.97)	0.013
<35%	0.73 (0.59–0.87)		0.33 (0.16–0.50)		0.32 (0.15–0.48)		0.92 (0.87–0.97)	
Study location								
East Asia	0.89 (0.75–1.00)	0.539	0.31 (0.00–0.62)	0.924	0.72 (0.55–0.90)	0.011	0.80 (0.67–0.93)	<0.001
Others	0.78 (0.67–0.88)		0.37 (0.22–0.51)		0.31 (0.21–0.41)		0.93 (0.90–0.96)	
<b>ATA US RSS</b>								
Study design								
Prospective	0.88 (0.58–1.00)	0.159	0.52 (0.12–0.92)	0.944	0.60 (0.04–1.00)	0.555	0.92 (0.81–1.00)	0.845
Retrospective	0.71 (0.50–0.91)		0.50 (0.35–0.65)		0.44 (0.24–0.65)		0.90 (0.85–0.95)	
No. of nodules								
>140	0.75 (0.53–0.97)	0.778	0.60 (0.48–0.71)	0.015	0.42 (0.21–0.63)	0.414	0.91 (0.86–0.96)	0.764
<140	0.70 (0.34–1.00)		0.28 (0.12–0.45)		0.62 (0.22–1.00)		0.88 (0.74–1.00)	
Prevalence of malignance								
>35%	0.89 (0.78–1.00)	0.073	0.48 (0.26–0.69)	0.833	0.67 (0.46–0.87)	0.052	0.87 (0.79–0.96)	0.014
<35%	0.55 (0.30–0.79)		0.52 (0.34–0.70)		0.31 (0.13–0.49)		0.93 (0.88–0.97)	
Study location								
East Asia	0.94 (0.85–1.00)	0.032	0.56 (0.29–0.84)	0.719	0.70 (0.40–1.00)	0.163	0.87 (0.74–0.99)	0.053
Others	0.62 (0.42–0.82)		0.48 (0.32–0.64)		0.39 (0.20–0.58)		0.91 (0.87–0.96)	
<b>K-TIRADS</b>								
No. of nodules								
>140	0.99 (0.94–1.00)	0.103	0.19 (0.05–0.63)	0.232	0.57 (0.43–0.71)	0.014	0.89 (0.85–0.92)	0.052
<140	0.98 (0.85–1.00)		0.34 (0.25–1.00)		0.05 (0.01–0.17)		1.00 (1.00–1.00)	
Prevalence of malignance								
>35%	0.99 (0.94–1.00)	0.103	0.19 (0.05–0.63)	0.232	0.61 (0.42–0.79)	0.041	0.88 (0.82–0.95)	0.020
<35%	0.98 (0.85–1.00)		0.34 (0.25–1.00)		0.21 (0.01–0.44)		0.95 (0.90–1.00)	
Study location								
East Asia	0.99 (0.94–1.00)	0.103	0.19 (0.05–0.63)	0.232	0.61 (0.42–0.79)	0.041	0.88 (0.82–0.95)	0.020
Others	0.98 (0.85–1.00)		0.34 (0.25–1.00)		0.21 (0.01–0.44)		0.95 (0.90–1.00)	
<b>TIRADS by Kwak et al.</b>								
No. of nodules								
>140	0.99 (0.96–1.00)	0.011	0.11 (0.00–0.22)	0.394	0.06 (0.01–0.12)	0.978	1.00 (0.99–1.00)	0.012
<140	0.94 (0.80–1.00)		0.25 (0.00–0.50)		0.15 (0.03–0.26)		1.00 (0.98–1.00)	
Prevalence of malignance								
>35%	0.98 (0.94–1.00)	0.028	0.13 (0.01–0.27)	0.638	0.15 (0.06–0.23)	<0.001	0.99 (0.97–1.00)	0.713
<35%	0.96 (0.87–1.00)		0.20 (0.02–0.43)		0.05 (0.01–0.09)		1.00 (0.99–1.00)	
Study location								
East Asia	0.96 (0.90–1.00)	<0.001	0.22 (0.10–0.33)	<0.001	0.14 (0.10–0.19)	<0.001	0.99 (0.98–1.00)	<0.001
Others	1.00 (1.00–1.00)		0.02 (–0.01–0.05)		0.01 (0.00–0.03)		1.00 (1.00–1.00)	

US RSS, ultrasound risk stratification systems; CrI, credible interval; ACR, American College of Radiology; TIRADS, Thyroid Imaging Reporting and Data System; ATA, American Thyroid Association; K, Korean Society of Thyroid Radiology.